Mochida Pharmaceutical Co., Ltd. (Headquarters: Tokyo, Japan, President: Naoyuki Mochida, hereinafter: Mochida) announced that “Teriparatide BS Subcutaneous Injection Kit 600μg MOCHIDA” (Development code: RGB-10) has been launched in Japan as the NHI (National Health Insurance) Drug Price has been listed today.
The product is a biosimilar of teriparatide (genetical recombination) which Mochida has developed in Japan based on a comprehensive license and collaboration agreement with Gedeon Richter Plc. in Hungary, and is a treatment for osteoporosis that enhances bone formation and improves bone structure. It is a disposable kit preparation with delivery device and available for self-injection.
As the first teriparatide (genetical recombination) biosimilar in Japan, Mochida believes that the product will contribute to improving the Quality of Life and to reducing the financial burden of patients with osteoporosis.
Brand name: Teriparatide BS Subcutaneous Injection Kit 600μg MOCHIDA
Generic Name: Teriparatide (Genetical Recombination) [Teriparatide Biosimilar 1]
Ingredients and Contents: Aqueous injection containing 600µg Teriparatide (Genetical Recombination) [Teriparatide Biosimilar 1] in 1 kit
Indications: Osteoporosis at high risk of fracture
Dosage and Administration: The usual adult dose is 20 μg of Teriparatide (genetical recombination) [teriparatide biosimilar 1] administered by subcutaneous injection once a day. The maximum total duration of treatment with Teriparatide should be 24 months.
Package: Kit: 2.4 mL × 1
NHI Drug Price: Teriparatide BS Subcutaneous Injection Kit 600μg MOCHIDA 26,491 Yen
Approval Date: September 20, 2019
NHI Drug Price Listing Date: November 27, 2019
Launch Date: November 27, 2019
Manufacturer/ Distributor: Mochida Pharmaceutical Co., Ltd
To read more Press Release articles, click here.